After AI express, investors ask on the investor interaction platform: what is the proportion of ritonavir API intermediates of your company mainly sold to China or abroad, and what are the main customers of this product?
Jinghua Pharmaceutical Group Co.Ltd(002349) (002349. SZ) said on the investor interaction platform on February 18 that the intermediates of senxuan pharmaceutical ritonavir series, a subsidiary, are mainly sold to China. The customer information is the company’s trade secret, and the company will perform the obligation of information disclosure in strict accordance with the requirements of relevant laws and regulations.
